- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Indaptus sichert neue Patente in Asien und Israel für Decoy-Plattform | 1 | Investing.com Deutsch | ||
| Di | Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments | 1 | GlobeNewswire (USA) | ||
| 12.02. | Indaptus Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 05.02. | Indaptus Therapeutics weitet Krebsstudie auf Kanada aus | 1 | Investing.com Deutsch | ||
| 05.02. | Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 | 77 | GlobeNewswire (Europe) | NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral... ► Artikel lesen | |
| 31.01. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.01. | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.01. | Indaptus Therapeutics looks to raise $2.25M in private placement | 1 | Seeking Alpha | ||
| INDAPTUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 | 136 | GlobeNewswire (Europe) | NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral... ► Artikel lesen | |
| 23.12.24 | Indaptus Therapeutics files to sell 1.94M shares of common stock | 4 | Seeking Alpha | ||
| 23.12.24 | Indaptus Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.11.24 | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.11.24 | Indaptus sichert sich 2,1 Millionen US-Dollar durch Aktien- und Optionsscheinverkauf | 6 | Investing.com Deutsch | ||
| 22.11.24 | Indaptus Therapeutics announces $2.135M registered direct offering | 1 | Seeking Alpha | ||
| 22.11.24 | Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 22.11.24 | Indaptus secures $2.1 million through stock and warrants sale | 1 | Investing.com | ||
| 12.11.24 | Indaptus Therapeutics GAAP EPS of -$0.32 | 1 | Seeking Alpha | ||
| 12.11.24 | Indaptus Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.24 | Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology | 2 | GlobeNewswire (USA) | ||
| 07.11.24 | Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting | 119 | GlobeNewswire (Europe) | NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer... ► Artikel lesen |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,771 | -3,38 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,844 | +1,44 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,488 | -0,31 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,538 | +0,66 % | Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results | Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,030 | -14,29 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,715 | -7,74 % | EQS-News: Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr gut" | EQS-News: Bio-Gate AG
/ Schlagwort(e): Studienergebnisse/Sonstiges
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,908 | +1,34 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,447 | +2,20 % | Vaxart reports promising norovirus vaccine trial results | ||
| BURCON NUTRASCIENCE | 0,054 | +5,88 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,930 | -100,00 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,292 | +3,55 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,085 | -0,37 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in March | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in March
03.03.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,118 | -5,60 % | AIM ImmunoTech Inc.: AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza | Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strainsOCALA, Fla., Feb. 28, 2025(NYSE American: AIM) ("AIM" or the "Company") today announced that Paul Goepfert... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,114 | +1,79 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,311 | +0,84 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen |
Das Unternehmen INDAPTUS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,849 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INDAPTUS THERAPEUTICS INC finden Sie auf Wallstreet Online.
